Piramal Pharma Opens New Microbiology Lab in Kentucky

Piramal Pharma Solutions (PPS), has opened a new microbiology laboratory at its sterile injectable facility in Lexington, Kentucky—marking a significant step forward in its ongoing $85 million Lexington expansion aimed at enhancing commercial-scale capabilities and improving operational efficiency.

Nathan Richardson, VP and Site Head, Piramal Pharma Solutions Lexington, said, “By enhancing sterility testing and microbiological quality capabilities, we are further strengthening our ability to support clients with high quality, reliable, and responsive services throughout the product life cycle.”

About the New Lab

Released for routine GMP use on September 11, 2026, the new laboratory soon received conditional approval for its sterility testing suite, making it one of the expansion’s first major components to come online. The full manufacturing expansion is expected to be operational by late 2027.

The new lab more than triples the site’s existing microbiology testing space, supporting improved laboratory workflow and providing additional capacity to accommodate future growth. The added space features three new biosafety cabinets, allowing PPS to run concurrent tests and reduce sample queue times. All incubators have also been consolidated within the new lab, further streamlining workflow and improving monitoring and accessibility across testing activities.

A key element of the lab is a dedicated sterility testing suite with a Grade C background environment, representing a major upgrade from the previously non-classified area. At its center is a fully integrated, Grade A sterility testing isolator that doubles the site’s sterility testing capacity and allows multiple samples to be processed simultaneously. By supporting both open and closed filtration methods, the new isolator provides greater flexibility to meet a wider range of product testing requirements. The area also includes built-in pass-throughs to move samples directly from the manufacturing floor to the lab, reducing contamination risk and protecting product integrity.

These enhancements are expected to reduce testing times by up to 50%, accelerating batch releases, minimizing bottlenecks, and smoothing transitions as programs move from clinical to commercial stages. The new infrastructure also reinforces the site’s contamination control and sterility assurance capabilities, while the added capacity reduces supply risk and prepares the site for commercial-scale demand.